| Literature DB >> 24911522 |
Waldemar Gozdzik1, Barbara Adamik1, Anna Gozdzik2, Maciej Rachwalik2, Wojciech Kustrzycki2, Andrzej Kübler1.
Abstract
OBJECTIVE ANDEntities:
Mesh:
Substances:
Year: 2014 PMID: 24911522 PMCID: PMC4049597 DOI: 10.1371/journal.pone.0098923
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of patients.
| Patients with suPAR level within normal range, n = 31 | Patients with suPAR level above normal range, n = 29 |
| |
|
| 3.3 (2.7–3.7) | 5.1 (4.7–5.5) | 0,0001 |
|
| 5/26 | 6/23 | n.s. |
|
| 64 (59–70) | 64 (57–73) | n.s. |
|
| 80 (70–87) | 82 (74–90) | n.s. |
|
| 55 (50–60) | 57 (55–65) | n.s. |
|
| |||
| Previous myocardial infarction | 24 (77) | 22 (76) | |
| Arterial hypertension | 27 (87) | 24 (83) | |
| Left main stenosis | 5 (16) | 5 (17) | |
| Triple vessel disease | 22 (71) | 25 (86) | |
|
| |||
| Beta blockers | 20 (65) | 21 (72) | |
| ACE inhibitors | 17 (55) | 21 (72) | |
| Calcium blockers | 10 (32) | 5 (17) | |
| Nitrates | 13 (42) | 9 (31) | |
|
| |||
| 2 | 6 (19) | 9 (31) | |
| 3 | 20 (65) | 19 (66) | |
| 4 | 5 (16) | 1 (3) | |
|
| 233 (210–240) | 241 (210–260) | n.s. |
|
| 85 (77–108) | 79 (66–94) | n.s. |
|
| 45 (37–54) | 40 (35–44) | n.s. |
|
| 8.1 (6.5–8.5) | 9.8 (6.5–9.5) | n.s. |
*ACE inhibitors, angiotensin-converting-enzyme inhibitor; CPB, cardiopulmonary bypass. Data presented as medians with 25th and 75th percentiles.
Indices of systemic inflammatory reaction in group 1(n = 31) and group 2(n = 29), measured at three time intervals.
| Baseline | 6 hours after surgery | 24 hours after surgery | ||||
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
|
| 4.0 | 3.9 | not done | not done | 106.0 | 123 |
|
| (3.3–8.0) | (3.1–14) | (76.3–158.7) | (113–171) | ||
|
| 9.5 | 8.6 | 10.2 | 10.9 | 8.7 | 10.3 |
|
| (7.4–12.5) | (7.6–9.5) | (7.6–11.4) | (9.1–12.3) | (8.0–11.2) | (9.1–12.4) |
|
| 5.1 | 8.4 | 84.2 | 65.2 | 43.0 | 52.2 |
|
| (2.2–11.4) | (3.4–12.0) | (61.0–115.0) | (35.3–107.0) | (28.8–75.4) | (29.8–70.8) |
|
| 5.9 | 5,4 | 35.7 | 35.8 | 19.3 | 19.2 |
|
| (1.9–14.1) | (1.5–12.1) | (26.5–58.7) | (28.3–68.2) | (13.9–24.4) | (14.6–28.5) |
|
| 37.4 | 24.2 | 50.5 | 45.1 | 41.9 | 39.3 |
|
| (11.3–46.8) | (10.2–40.3) | (19.7–56.5) | (24.2–80.5) | (19.7–65.5) | (33.7–43.5) |
CRP, c-reactive protein; WBC, white blood cell count; IL-6, interleukin 6; IL-8, interleukin 8; TNF alpha, tumor necrosis factor-alpha. Data presented as medians with 25th and 75th percentiles;
*p<0.05 compared to the baseline;
p<0.0001 compared to the baseline.
Figure 1Plasma levels of suPAR measured at baseline (open squares), 6 hours (closed squares), and 24 hours (triangles) after surgery.
Data are presented as medians (middle point) with 25th and 75th percentiles (box) and min-max values (whiskers); * p<0.001, a comparison between groups.
Indices of organ damage measured in group 1(n = 32) and group 2(n = 29) measured at three time intervals.
| Baseline | 6 hours after surgery | 24 hours after surgery | ||||
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
|
| 0,5 | 0.4 | 0.7 | 0.6 | 37.0 | 37.2 |
|
| (0.0–2.3) | (0.0–0.6) | (0.0–5.8) | (0.0–13.7) | (13.0–49.0) | (10.3–76.4) |
|
| 0.02 | 0.02 | 6.2 | 4.2 | 4.4 | 2.5 |
|
| (0.01–0.1) | (0.01–0.1) | (3.5–11.9) | (2.8–5.3) | (1.5–8.5) | (1.3–8.4) |
|
| 110.7 | 113.1 | 159.0 | 173.2 | 154.7 | 130.4 |
|
| (81.8–142.2) | (86.8–138.7) | (128.1–201.3) | (122.2–217.9) | (108.7–183.4) | (101.5–158.2) |
|
| 0.8 | 0.9 | 0.8 | 0.9 | 0.9 | 0.9 |
|
| (0.7–1.0) | (0.7–1.1) | (0.6–0.9) | (0.8–1.1) | (0.9–0.9) | (0.7–1.1) |
|
| 32 | 32 | 36 | 32 | 44 | 33 |
|
| (29–43) | (29–45) | (31–43) | (29–47) | (43–46) | (25–50) |
|
| 22 | 29 | 28 | 35 | 37 | 57 |
|
| (15–27) | (18–42) | (24–44) | (31–57) | (29–130) | (37–109) |
|
| 22 | 35 | 26 | 32 | 28 | 39 |
|
| (16–41) | (32–52) | (17–40) | (21–41) | (18–51) | (30–55) |
|
| 204 | 244 | 153 | 149 | 147 | 147 |
|
| (188–229) | (184–276) | (145–198) | (113–185) | (134–157) | (123–164) |
NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NGAL, neutrophil gelatinase associated lipocalin; AST, aspartate.
Data presented as medians with 25th and 75th percentiles;
*p<0.05 compared to the baseline;
p<0.0001 compared to the baseline.